1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijpmbs@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers.[Read More]
 

Comparative Evaluation of Efficacy and Safety Profile of Febuxostat with Allopurinol in Patients with Hyperuricemia and Gout

Bijay Kumar and P K Agarwal
Department of Pharmacology, Rama Medical College- Hospital & Research Centre, Mandhana, Kanpur- 209217 (U.P.)
Abstract—Gout is known to be a metabolic disease mostly affecting the elderly. Treatment and management becomes all the more difficult in this age group because of presence of co-morbidity (like Hypertension, Diabetes Mellitus, Renal and Cardiovascular diseases) and concomitant use of medication which at times do not agree with the usual hypouricemic drugs used in gout. The objective of this study was to compare the effect and side effect of Allopurinol with Febuxostat, a relatively new uric acid lowering drug. Subjects between 30 - 55 years having serum uric acid level > 8.0 mg were enrolled in this randomized trial to receive either Allopurinol (100 mg thrice a day) or Febuxostat (40 mg once daily) for a period of 3 months. Febuxostat (40 mg once daily) was more effective than Allopurinol (100 mg thrice a day) in lowering serum uric acid at 3 months. Serum uric acid came below 6 mg/dl in >62% of Febuxostat treated patients as compared to Allopurinol group where it came down in only <38% of cases. Flaring of gouty arthritis was nil in Febuxostat group while 7 patients showed drug related problem in Allopurinol group. Compliance to drug therapy was much better in Febuxostat group.

Index Terms—Gout, Febuxostat, Allopurinol, Efficacy, Adverse effect

Cite: Bijay Kumar and P K Agarwal, "Comparative Evaluation of Efficacy and Safety Profile of Febuxostat with Allopurinol in Patients with Hyperuricemia and Gout," International Journal of Pharma Medicine and Biological Sciences, Vol. 2, No. 4, pp. 52-56, October 2013.
Copyright © 2012-2019 International Journal of Pharma Medicine and Biological Sciences, All Rights Reserved
E-mail: ijpmbs@ejournal.net